Association of mutation and low expression of the CTCF gene with breast cancer progression

CTCF encodes 11-zinc finger protein which is implicated in multiple tumors including the carcinoma of the breast. The Present study investigates the association of CTCF mutations and their expression in breast cancer cases. A total of 155 breast cancer and an equal number of adjacent normal tissue s...

Full description

Saved in:
Bibliographic Details
Published in:Saudi pharmaceutical journal 2020-05, Vol.28 (5), p.607-614
Main Authors: Akhtar, Md. Salman, Akhter, Naseem, Najm, Mohammad Zeeshan, Deo, S.V.S, Shukla, N.K., Almalki, Shaia Saleh R., Alharbi, Raed A., Sindi, Abdulmajeed Abdulghani A., Alruwetei, Abdulmohsen, Ahmad, Abrar, Husain, Syed Akhtar
Format: Article
Language:English
Subjects:
Breast cancer
CTCF
Immunohistochemistry
Mutation
PCR-SSCP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CTCF encodes 11-zinc finger protein which is implicated in multiple tumors including the carcinoma of the breast. The Present study investigates the association of CTCF mutations and their expression in breast cancer cases. A total of 155 breast cancer and an equal number of adjacent normal tissue samples from 155 breast cancer patients were examined for CTCF mutation(s) by PCR-SSCP and automated DNA sequencing. Immunohistochemistry (IHC) method was used to analyze CTCF expression. Molecular findings were statistically analyzed with various clinicopathological features to identify associations of clinical relevance. Of the total, 16.1% (25/155) cases exhibited mutation in the CTCF gene. Missense mutations Gln > His (G > T) in exon 1 and silent mutations Ser > Ser (C > T) in exon 4 of CTCF gene were analyzed. A significant association was observed between CTCF mutations and some clinicopathological parameters namely menopausal status (p = 0.02) tumor stage (p = 0.03) nodal status (p = 0.03) and ER expression (p = 0.04). Protein expression analysis showed 42.58% samples having low or no expression (+), 38.0% with moderate (++) expression and 19.35% having high (+++) expression for CTCF. A significant association was found between CTCF protein expression and clinicopathological parameters include histological grade (p = 0.04), tumor stage (p = 0.04), nodal status (p = 0.03) and ER status (p = 0.04). The data suggest that CTCF mutations leading to its inactivation significantly contribute to the progression of breast cancer.
ISSN:1319-0164
2213-7475
DOI:10.1016/j.jsps.2020.03.013